GlaxoSmithKline: Substance-Related Disorders trials
The registry lists 12 Substance-Related Disorders studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 11Phase 2 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Effects of the D3 Antagonist GSK598809 on Food Reward and ReinforcementCompletedNCT01039454Phase 1
- GSK618334 Repeat Dose StudyCompletedNCT01036061Phase 1
- Effects of GSK598809 on Brain Activation in Abstinent AlcoholicsWithdrawnNCT00908206Phase 1
- EtOH Interaction StudyCompletedNCT00887367Phase 1
- An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET LigandCompletedNCT00814957Phase 1
- Relapse Prevention Study in Newly Abstinent SmokersWithdrawnNCT00793468Phase 2
- A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.CompletedNCT00728897Phase 1
- A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy SmokersCompletedNCT00728052Phase 1
- A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine RewardCompletedNCT00605241Phase 1
- To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334CompletedNCT00513279Phase 1
- A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809CompletedNCT00437840Phase 1
- Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809CompletedNCT00437632Phase 1